Review of antibiotic resistance, antibiotic treatment and prevention of pneumococcal pneumonia

Klugman, 1990, Pneumococcal resistance to antibiotics, Clin Microbiol Rev, 3, 171, 10.1128/CMR.3.2.171 Whitney, 2000, Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States, N Engl J Med, 343, 1917, 10.1056/NEJM200012283432603 Doern, 2001, Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resista rates since 1994–1995, Antimicrob Agents Chemother, 45, 1721, 10.1128/AAC.45.6.1721-1729.2001 Kaplan, 2002, Six-year multicenter surveillance of invasive pneumococcal infections in children, Pediatr Infect Dis J, 21, 141, 10.1097/00006454-200202000-00011 Hyde, 2001, Macrolide resistance among invasive Streptococcus pneumoniae isolates, JAMA, 286, 1857, 10.1001/jama.286.15.1857 Schmitz, 2001, Molecular surveillance of macrolide, tetracycline and quinolone resistance mechanisms in 1191 clinical European Streptococcus pneumoniae isolates, Int J Antimicrob Agents, 18, 433, 10.1016/S0924-8579(01)00427-7 Adrian, 1997, Mutations in the dihydrofolate reductase gene of trimethoprim-resistant isolates of Streptococcus pneumoniae, Antimicrob Agents Chemother, 41, 2406, 10.1128/AAC.41.11.2406 Hooper, 2001, Emerging mechanisms of fluoroquinolones resistance, Emerg Infect Dis, 7, 337, 10.3201/eid0702.010239 Kaplan, 1998, Management of infections due to antibiotic-resistant Streptococcus pneumoniae, Clin Microbiol Rev, 11, 628, 10.1128/CMR.11.4.628 American Academy of Pediatrics, 2000, Pneumococcal infections, 457 Pallares, 1987, Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci, N Engl J Med, 317, 18, 10.1056/NEJM198707023170104 Pallares, 1995, Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain, N Engl J Med, 333, 474, 10.1056/NEJM199508243330802 Plouffe, 1996, Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention, JAMA, 275, 194, 10.1001/jama.275.3.194 Metlay, 2000, Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia, Clin Infect Dis, 30, 520, 10.1086/313716 Feikin, 2000, Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997, Am J Public Health, 90, 223, 10.2105/AJPH.90.2.223 Moroney, 2001, Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance, Clin Infect Dis, 33, 797, 10.1086/322623 Friedland, 1995, Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease, Pediatr Infect Dis J, 14, 885, 10.1097/00006454-199510000-00013 Deeks, 1999, Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae, Pediatrics, 103, 409, 10.1542/peds.103.2.409 Choi, 1998, Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children, Clin Infect Dis, 26, 1346, 10.1086/516340 Tan, 1998, Clinical characteristics and outcome of children with pneumonia attributable to pencillin-susceptible and pencillin nonsusceptible Streptococcus pneumoniae, Pediatrics, 102, 1369, 10.1542/peds.102.6.1369 Hardie, 1998, Complicated parapneumonic effusions in children caused by penicillin-nonsusceptible Streptococcus pneumoniae, Pediatrics, 101, 388, 10.1542/peds.101.3.388 Kaplan, 2001, Outcome of invasive infections outside the central nervous system caused by Streptococcus pneumoniae isolates nonsuceptible to ceftriaxone in children treated with beta-lactam antibiotics, Pediatr Infect Dis J, 20, 392, 10.1097/00006454-200104000-00005 Mufson, 1999, Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978–1997, Am J Med, 107, 34S, 10.1016/S0002-9343(99)00098-4 Waterer, 2001, Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia, Arch Intern Med, 161, 1837, 10.1001/archinte.161.15.1837 Buckingham, 1998, Break-through bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia, J Pediatr, 132, 174, 10.1016/S0022-3476(98)70510-4 Reid, 1995, Pneumococcal meningitis during therapy of otitis media with clarithromycin, Pediatr Infect Dis J, 14, 1104, 10.1097/00006454-199512000-00016 Jackson, 1996, Breakthrough sepsis in macrolide-resistant pneumococcal infection, Pediatr Infect Dis J, 15, 1049, 10.1097/00006454-199611000-00026 Kelley, 2000, Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin, Clin Infect Dis, 31, 1008, 10.1086/318157 Bochud, 2001, Breakthrough Streptococcus pneumoniae meningitis during clarithromycin therapy for acute otitis media, Eur J Microbiol Infect Dis, 20, 136, 10.1007/PL00011244 Kaplan, 2001, Linezolid for the treatment of community-acquired pneumonia in hospitalized children, Pediatr Infect Dis J, 20, 488, 10.1097/00006454-200105000-00004 Heffelfinger, 2000, Management of community-acquired pneumonia in the era of pneumococcal resistance. A report from the Drug-resistant of pneumococcal resistance. A report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group, Arch Intern Med, 160, 1399, 10.1001/archinte.160.10.1399 Bartlett, 2000, Practice guidelines for the management of community-acquired pneumonia in adults, Clin Infect Dis, 31, 347, 10.1086/313954 Rennels, 1998, Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants, Pediatrics, 101, 604, 10.1542/peds.101.4.604 Black, 2000, Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children, Pediatr Infect Dis J, 19, 187, 10.1097/00006454-200003000-00003 Centers for Disease Control and Prevention, 2000, Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR, 49, 1 American Academy of Pediatrics, 2000, Committee on Infectious Diseases. Policy statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococccal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis, Pediatrics, 106, 362, 10.1542/peds.106.2.362 Black, 2001, Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugatevaccine, Pediatr Infect Dis J, 20, 1105, 10.1097/00006454-200112000-00002 Whitney, 2003, Decline in invasive pneumococcal disease after the introduction of protein-conjugate polysaccharide conjugate vaccine, N Engl J Med, 348, 1737, 10.1056/NEJMoa022823